野村发布研报称，预计京东健康2025年下半年业绩将好过市场预期，主要因2025年第四季流感病例激增 带动药品需求上升。野村预估，京东健康2025年第四季营收将达200亿元人民币，按年增长22%，受惠 来自药品/营养品/医疗器材业务分别实现30%、20%及10%按年销售增长。2025年第四季流感病例扩散 带动相关药品，占药品销售额高单位数百分比，及医疗设备如家用氧气浓缩机销售。与此同时，营养品 牌在2025年第四季持续推行有效营销活动，强化其稳健增长态势。 中金指出，2025年内逐季来看，该行观察到京东健康收入端表现强劲，1-3Q25单季度均实现25%左右的 同比增速。根据3Q25末披露公告，公司在3Q25期间与礼来、信达生物、拜耳中国等药企签署战略合作 协议，不断强化新药全网首发的业务特色。考虑到年内原研药品类持续放量的趋势依旧，叠加4Q25以 来冬季流感防控需求渐起，该行判断4Q25公司亦有望实现收入端强劲表现，该行预计公司2025年全年 收入同比增速有望接近25%。 智通财经APP获悉，京东健康(06618)午前涨超6%，截至发稿，涨6.53%，报62港元，成交额4.11亿港 元。 ...

京东健康(06618)午前涨超6%，截至发稿，涨6.53%，报62港元，成交额4.11亿港元。 野村发布研报称，预计京东健康2025年下半年业绩将好过市场预期，主要因2025年第四季流感病例激增 带动药品需求上升。野村预估，京东健康2025年第四季营收将达200亿元人民币，按年增长22%，受惠 来自药品/营养品/医疗器材业务分别实现30%、20%及10%按年销售增长。2025年第四季流感病例扩散 带动相关药品，占药品销售额高单位数百分比，及医疗设备如家用氧气浓缩机销售。与此同时，营养品 牌在2025年第四季持续推行有效营销活动，强化其稳健增长态势。 中金指出，2025年内逐季来看，该行观察到京东健康收入端表现强劲，1-3Q25单季度均实现25%左右的 同比增速。根据3Q25末披露公告，公司在3Q25期间与礼来、信达生物、拜耳中国等药企签署战略合作 协议，不断强化新药全网首发的业务特色。考虑到年内原研药品类持续放量的趋势依旧，叠加4Q25以 来冬季流感防控需求渐起，该行判断4Q25公司亦有望实现收入端强劲表现，该行预计公司2025年全年 收入同比增速有望接近25%。 ...

消息面上，野村发表报告，预计京东健康2025年下半年业绩将好过市场预期，主要因2025年第四季流感 病例激增带动药品需求上升。该机构预估京东健康2025年第四季营收将达200亿元人民币，按年增长 22%，受惠来自药品/营养品/医疗器材业务分别实现30%、20%及10%按年销售增长。2025年第四季流感 病例扩散带动相关药品，占药品销售额高单位数百分比，及医疗设备如家用氧气浓缩机销售。与此同 时，营养品牌在2025年第四季持续推行有效营销活动，强化其稳健增长态势。 中金发布研报称，考虑到原研品类放量趋势依旧且流感品种需求强劲，上调京东健康25年及26年收入预 测2%至725亿元及817亿元，同时考虑毛利率改善趋势及潜在利息收入波动的综合影响，该行分别上调 25年及26年non-IFRS净利润4%及1%至65亿元及64亿元。首次引入27年收入预测912亿元及non-IFRS净 利润预测68亿元。考虑到近期板块表现略有波动，基于SOTP维持目标价71.4港币不变(23%上行空间)， 维持跑赢行业评级。 金吾财讯 | 京东健康(06618)股价上行，截至发稿，涨5.58%，报61.45港元，成交额2.3亿港元。 消息 ...

野村发表报告，预计京东健康2025年下半年业绩将好过市场预期，主要因第四季流感病例激增带动药品 需求上升。野村预估京东健康2025年第四季营收将达200亿元，按年增长22%，受惠来自药品/营养品/医 疗器材业务分别实现30%、20%及10%按年销售增长。第四季流感病例扩散带动相关药品，占药品销售 额高单位数百分比，及医疗设备如家用氧气浓缩机销售。与此同时，营养品牌在第四季持续推行有效营 销活动，强化其稳健增长态势。 ...

在博世新能源汽车核心部件及自动驾驶研发制造基地，范波详细了解核心部件研发、智能制造流程，对企业 多次投资加码苏州表示赞赏。他希望企业坚定发展信心，推动更多前沿技术和高端项目落地苏州。来到三星电子 （苏州）半导体有限公司，范波参观企业展厅，听取生产运营情况介绍，鼓励企业提升先进制造能级，不断增强 全球市场竞争力。 昨天（1月5日），市委书记范波调研我市外资企业发展工作。他强调，要深入学习贯彻党的二十届四中全会 精神和习近平总书记会见国际工商界代表时的重要讲话精神，认真落实党中央、国务院决策部署及省委、省政府 工作要求，突出创新引领，强化开放赋能，打造一流营商环境，不断增创高水平开放新优势，为苏州高质量发展 提供有力支撑。 倪黎祥 摄 外资企业是中国式现代化的重要参与者，是中国改革开放和创新创造的重要参与者，是中国联通世界、融入 经济全球化的重要参与者。范波强调，要坚定不移扩大对外开放，深化开放创新综合试验，鼓励外资企业利润再 投资和设立研发中心、地区总部，提升城市产业发展核心竞争力。要着力打造市场化、法治化、国际化一流营商 环境，维护市场公平竞争，健全外商投资全生命周期服务保障体系，深入开展服务企业、服务项目、 ...

报告导读： 药品流通行业是国家医疗卫生事业和健康产业的重要组成部分，是关系人民健康和生命安全的重要行业。批发商在药品流通渠道中作为产品销售承上启下的 环节，是降低药品流通成本和降低药价的关键所在。随着"两票制"改革落实和国民医疗卫生意识地不断增强，我国医药流通市场规模保持增长趋势。2024年 我国药品流通行业销售额29470亿元，其中，药品批发销售额22970亿元，占77.94%；药品零售额6500亿元，占22.06%。从区域分布来看，华东36.3%，中南 27.0%，华北15.2%，西南13.4%，东北4.3%，西北3.8%。其中，华东、中南、华北三大区域销售额占全国销售总额的78.5%。从销售品类来看，西药类销售 额占据主要份额，占比高达70.8%，其次是中成药类，销售额占14.6%，医疗器材类销售额占7.7%，中药材类销售额占2.4%，化学试剂类销售额占0.6%，玻 璃仪器类销售额占比不到0.1%，其他类销售额占3.9%。 为探究药品流通行业变化趋势（怎么变）、用户需求（要什么）、投放选择（投向哪）、运营方法（如何投）及实践案例（看一看），智研咨询发布了 《2026-2032年中国药品流通行业市场竞争策 ...

Core Insights - The pharmaceutical distribution industry is a crucial component of the national healthcare system and health industry, significantly impacting public health and safety [1][7] - The industry is experiencing growth due to the implementation of the "two-invoice system" reform and increasing public awareness of healthcare [1][7] Industry Overview - The pharmaceutical distribution market in China is projected to reach a sales volume of 29,470 billion yuan in 2024, with wholesale sales accounting for 22,970 billion yuan (77.94%) and retail sales for 6,500 billion yuan (22.06%) [1][7] - The regional distribution of sales shows that East China accounts for 36.3%, Central South 27.0%, North China 15.2%, Southwest 13.4%, Northeast 4.3%, and Northwest 3.8%, with the top three regions contributing to 78.5% of total sales [9][10] Sales Structure - The sales composition indicates that Western medicine accounts for 70.8% of total sales, followed by traditional Chinese medicine at 14.6%, medical devices at 7.7%, and other categories [9][10] Current State of the Industry - As of the end of 2024, there are 705,400 licensed pharmaceutical businesses in China, including 15,100 wholesale companies and 66,070 retail chain enterprises [3][5] - The total number of retail pharmacies has increased to 683,700, with a notable rise in single retail pharmacies [3][5] Financial Performance - In 2024, the main business income of reported pharmaceutical distribution enterprises reached 22,431 billion yuan, reflecting a 0.8% increase from 2023, while the profit totaled 468 billion yuan with an average gross margin of 7.2% [5][6] Industry Chain - The pharmaceutical distribution industry serves as a critical link in the pharmaceutical supply chain, connecting manufacturers with end-users, including hospitals and pharmacies [11][12] Competitive Landscape - Major players in the pharmaceutical distribution sector include East China Pharmaceutical, Shanghai Pharmaceutical, China National Pharmaceutical Group, and others, with significant revenue contributions from these companies [14][15] Future Development Directions - The industry aims to enhance operational efficiency and inventory management to ensure a stable supply of pharmaceuticals while minimizing financial risks [18][19]

Group 1 - The company has slightly raised its adjusted operating margin forecast, now expecting it to be between 11.3% and 11.8%, an increase of 50 basis points from previous expectations [1] - In the second quarter, the company's sales grew by 1% year-on-year, reaching €4.3 billion (approximately $4.98 billion) [1] - The company had previously lowered its annual profit forecast in May, attributing it to costs associated with tariffs, estimating potential losses of up to €300 million [1] Group 2 - A report from February indicated that the company paid €38 million in tariffs in the U.S. last year, highlighting the significant impact of tariffs on its operations [2] - The U.S. is the company's largest market, expected to account for about 40% of its sales in 2024, with one-third of its tax payments coming from this market [2] - The company imports various products from China, including respiratory masks and electric shavers, while also sourcing medical equipment from Europe [2]

Core Insights - Indonesia is shifting its trade allegiance from China to the United States, signing a significant $34 billion deal that includes key minerals, food procurement, and military equipment [1][3] - The deal includes a drastic reduction of tariffs on over 1,700 U.S. goods, while the U.S. secures critical access to Indonesian nickel resources, which are vital for various industries [3][4] - The U.S. aims to diversify its mineral supply chain, particularly in response to China's export controls on rare earth elements, with Indonesia's nickel seen as a strategic alternative [4][8] Group 1: Trade Dynamics - Indonesia's agreement with the U.S. includes a commitment to purchase 1 million tons of wheat annually, a 35% increase from the previous year, and prioritizes U.S. military equipment procurement [3] - The deal represents a significant shift in Indonesia's trade strategy, moving away from reliance on Chinese investments and resources [1][3] Group 2: Geopolitical Implications - The U.S. is leveraging Indonesia's nickel resources to mitigate the impact of China's rare earth export controls, which are crucial for military applications [4][8] - Other Southeast Asian countries, such as Vietnam and Cambodia, are also adjusting their trade policies in response to U.S. pressures, indicating a broader regional shift [6][8] Group 3: Strategic Resources - Indonesia holds the largest nickel reserves globally, and the U.S. is keen to access these resources to strengthen its supply chain for electric vehicle batteries and military alloys [4][11] - Despite the U.S. securing access to Indonesian nickel, China's control over the processing chain remains significant, with Chinese companies holding 60% of the nickel processing capacity [11]

Core Viewpoint - The European Union (EU) has decided to restrict Chinese medical device imports under the International Procurement Instrument (IPI) to counter perceived discrimination against foreign manufacturers in public procurement by Beijing [1][2]. Group 1: EU's Decision and Implications - The EU's decision prohibits Chinese companies from participating in public tender projects for medical devices valued over 5 million euros for the next five years [1]. - The EU China Chamber of Commerce expressed deep disappointment and concern over this decision, stating that it contradicts the principles of open markets and fair competition [1][2]. - The IPI is viewed as a unilateral tool by the EU, which may exacerbate the complexity of EU-China economic relations [1][2]. Group 2: Background and Context - The IPI was introduced in 2022 to allow the EU to investigate non-EU companies and impose restrictions on their market access, particularly targeting emerging economies like China [2]. - The EU initiated a nine-month investigation into public procurement in the Chinese medical device sector under the IPI, marking the first use of this regulation [2]. Group 3: Reactions and Future Negotiations - The EU China Chamber of Commerce highlighted that the EU's pursuit of "market equality" fails to consider the historical context, as European medical device companies have benefited from significant market access in China [3]. - There remains a possibility for an agreement between the EU and China to avoid further measures, with EU Trade Commissioner Valdis Dombrovskis indicating a willingness to negotiate [3]. - The Chinese Ministry of Commerce firmly opposes the EU's discriminatory measures, emphasizing the need for fair competition and warning of potential retaliatory actions [3].